IP6K2 and central nervous system cancer: To probe the biological effects of IP6K2 in gliomas, we used shRNAs or overexpression plasmids (OE) to inhibit or overexpress IP6K2 in U87 and U251 cells, and used RT-PCR to verify the transfection efficiency.